Randall Osborne. Show Affiliations »
Abstract
Mesh： See more » Antibodies, Monoclonal, HumanizedBiotechnology/legislation & jurisprudenceBiotechnology/standardsCarrier Proteins/adverse effectsCertolizumab PegolComplement C1 Inactivator Proteins/adverse effectsComplement C1 Inhibitor ProteinDrug ApprovalDrug-Related Side Effects and Adverse ReactionsHumansImmunoglobulin Fab Fragments/adverse effectsPolyethylene Glycols/adverse effectsReceptors, FcRecombinant Fusion Proteins/adverse effectsRecombinant Proteins/adverse effectsRotavirus Vaccines/adverse effectsThrombin/adverse effectsThrombin/geneticsThrombopoietinUnited StatesUnited States Food and Drug AdministrationVaccines, Attenuated/adverse effects
Substances： See more » Antibodies, Monoclonal, HumanizedCarrier ProteinsComplement C1 Inactivator ProteinsComplement C1 Inhibitor ProteinImmunoglobulin Fab FragmentsRIX4414 vaccineReceptors, FcRecombinant Fusion ProteinsRecombinant ProteinsRotavirus VaccinesSERPING1 protein, humanVaccines, AttenuatedPolyethylene GlycolsrilonaceptThrombopoietinThrombinromiplostimCertolizumab Pegol
Year: 2009 PMID： 19270664 DOI： 10.1038/nbt0309-222
Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908